Comparative Tolerability of Treatments for Inflammatory Bowel Disease

[1]  S. Targan,et al.  Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. , 2000, Gastroenterology.

[2]  B. Korelitz,et al.  Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease , 1998, American Journal of Gastroenterology.

[3]  S. Hanauer,et al.  Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. , 1999, Gastroenterology.

[4]  S. Targan,et al.  An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. , 1999, Gastroenterology.

[5]  S. Bickston,et al.  The relationship between infliximab treatment and lymphoma in Crohn's disease. , 1999, Gastroenterology.

[6]  B. Korelitz,et al.  Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine , 1999, American Journal of Gastroenterology.

[7]  S. Targan,et al.  Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. , 1999, Gastroenterology.

[8]  R. Issenman.  Bone mineral metabolism in pediatric inflammatory bowel disease , 1999 .

[9]  B. Bouscarel,et al.  Signal transduction and hepatocellular bile acid transport: cross talk between bile acids and second messengers. , 1999, Gastroenterology.

[10]  A. Buchman,et al.  Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. , 1999, Gastroenterology.

[11]  P. Rutgeerts,et al.  Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.

[12]  S. Hanauer,et al.  Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. , 1999, Inflammatory bowel diseases.

[13]  J. Valentine,et al.  Prevention and treatment of osteoporosis in patients with inflammatory bowel disease , 1999, American Journal of Gastroenterology.

[14]  D. Mack.  Cow's Milk and Constipation , 1999, American Journal of Gastroenterology.

[15]  J. Mary,et al.  A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease , 1999, American Journal of Gastroenterology.

[16]  M. Neurath,et al.  Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease , 1998, Gut.

[17]  Y. Kim,et al.  Short-chain fatty acids in ulcerative colitis. , 2009, Nutrition reviews.

[18]  M. Färkkilä,et al.  Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. , 1998, Gastroenterology.

[19]  A. Lavy,et al.  Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. , 1998, Gastroenterology.

[20]  R. D. De Abreu,et al.  Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[21]  B. Kirschner,et al.  Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. , 1998, Gastroenterology.

[22]  K. Fellermann,et al.  Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506) , 1998, American Journal of Gastroenterology.

[23]  D. Paterson,et al.  Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. , 1998, Transplantation.

[24]  S. Hanauer,et al.  Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. , 1998, Gastroenterology.

[25]  C. Record,et al.  Neoral May Be as Effective as Intravenous Cyclosporine in the Treatment of Steroid-Resistant Ulcerative Colitis , 1998, American Journal of Gastroenterology.

[26]  G. Radford-Smith,et al.  Treatment of steroid refractory inflammatory bowel disease (IBD) with mycophenolate mofetil (MMF) , 1998, Australian and New Zealand journal of medicine.

[27]  J. Markowitz.  Summary of the workshop on 6-mercaptopurine/azathioprine pharmacology. , 1998, Inflammatory bowel diseases.

[28]  J. Marion.  Toxicity of 6-mercaptopurine/azathioprine in patients with inflammatory bowel disease. , 1998, Inflammatory bowel diseases.

[29]  S. Swan,et al.  The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function , 1998, Clinical pharmacology and therapeutics.

[30]  S. Hanauer,et al.  A safety and efficacy study of recombinant human interleukin-10 (rHuIL-10) treatment in 329 patients with chronic active Crohn's disease (CACD) , 1998 .

[31]  E. Losada,et al.  Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease. , 1998, Clinical nephrology.

[32]  R. Schmid,et al.  Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. , 1998, The Journal of clinical investigation.

[33]  B. Korelitz.  Inflammatory bowel disease and pregnancy. , 1998, Gastroenterology clinics of North America.

[34]  J. Green,et al.  Inflammatory bowel disease and smoking : A review , 1998 .

[35]  G. Ciancio,et al.  Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients , 1998 .

[36]  B. Stotland,et al.  Newer treatments for inflammatory bowel disease. , 1996, Drugs of today.

[37]  Sandborn Wj.  Azathioprine: State of the Art in Inflammatory Bowel Disease , 1998 .

[38]  H. Steinhart,et al.  Combination ciprofloxacin and metronidazole for active Crohn's disease. , 1998, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[39]  G. Koren,et al.  The safety of mesalamine in human pregnancy: a prospective controlled cohort study. , 1998, Gastroenterology.

[40]  G. Becker,et al.  Suppression of the humoral immune response by mycophenolate mofetil. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  B. Feagan,et al.  Review article: Drug development in inflammatory bowel disease: budesonide—a model of targeted therapy , 1997, Alimentary pharmacology & therapeutics.

[42]  M. Peppercorn.  Antibiotics Are Effective Therapy for Crohn's Disease , 1997, Inflammatory bowel diseases.

[43]  B. Feagan.  Antibiotics Are Not Effective Therapy for Crohn's Disease (Time to Remove the Rose‐Coloured Glasses) , 1997, Inflammatory bowel diseases.

[44]  V. S. Wong,et al.  Treatment of corticosteroid‐resistant ulcerative colitis with heparin —a report of 16 cases , 1997, Alimentary pharmacology & therapeutics.

[45]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[46]  S. Hanauer,et al.  Cyclosporin for severe ulcerative colitis: a user's guide. , 1997, The American journal of gastroenterology.

[47]  C. Elson,et al.  Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. , 1997, Gastroenterology.

[48]  M. Campieri,et al.  Oral budesonide is as effective as oral prednisolone in active Crohn’s disease , 1997, Gut.

[49]  B. Sands.  Biologic Therapy for Inflammatory Bowel Disease , 1997, Inflammatory bowel diseases.

[50]  J. Marshall,et al.  Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. , 1997, Gut.

[51]  W. Sandborn.  Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. , 1997, The American journal of gastroenterology.

[52]  N. Dreyer,et al.  5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis. , 1997, The American journal of gastroenterology.

[53]  S B Love,et al.  The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation. , 1997, Gastroenterology.

[54]  J. Rombeau,et al.  10 Nutrition and ulcerative colitis , 1997 .

[55]  K. Batts,et al.  Transdermal Nicotine for Mildly to Moderately Active Ulcerative Colitis , 1997, Annals of Internal Medicine.

[56]  E. Conner,et al.  Effects of cyclosporine or FK506 in chronic colitis. , 1997, The Journal of pharmacology and experimental therapeutics.

[57]  F. Baert,et al.  Immunomodulator therapy of inflammatory bowel disease. , 1997, Acta clinica Belgica.

[58]  W. Sandborn.  A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. , 1996, The American journal of gastroenterology.

[59]  S. Hanauer,et al.  Review article: The medical management of Crohn's disease , 1996, Alimentary pharmacology & therapeutics.

[60]  R. Morris.  Mechanisms of Action of New Immunosuppressive Drugs , 1995, Kidney international. Supplement.

[61]  W. Sandborn,et al.  Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. , 1996, Mayo Clinic proceedings.

[62]  D. Jewell,et al.  Cytokines and mechanisms of action of glucocorticoids and aminosalicylates in the treatment of ulcerative colitis and Crohn's disease. , 1996, Alimentary pharmacology & therapeutics.

[63]  R. Brattsand,et al.  Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. , 1996, Alimentary pharmacology & therapeutics.

[64]  Sollinger Hw.  Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. , 1995 .

[65]  J. Compston.  osteoporosis, corticosteroids and inflammatory bowel disease , 1995 .

[66]  P. Rutgeerts,et al.  Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. , 1995, Gastroenterology.

[67]  J. Callen.  Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial , 1995 .

[68]  W. Sandborn.  A Critical Review of Cyclosporine Therapy in Inflammatory Bowel Disease , 1995 .

[69]  Loyd,et al.  Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. , 1995, The New England journal of medicine.

[70]  M. Weinblatt.  Methotrexate for chronic diseases in adults. , 1995, The New England journal of medicine.

[71]  G. Alarcón,et al.  Supplementation with Folic Acid during Methotrexate Therapy for Rheumatoid Arthritis: A Double-Blind, Placebo-Controlled Trial , 1994, Annals of Internal Medicine.

[72]  J. Soulé,et al.  Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease. , 1994, The New England journal of medicine.

[73]  M. Grisham.  Oxidants and free radicals in inflammatory bowel disease , 1994, The Lancet.

[74]  L. Raisz,et al.  Glucocorticoid-induced osteoporosis. , 1994, Rheumatic diseases clinics of North America.

[75]  M. Kamm,et al.  Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease , 1994, The Lancet.

[76]  Polisson Rp,et al.  Methotrexate: adverse reactions and major toxicities. , 1994 .

[77]  R G Newcombe,et al.  Transdermal nicotine for active ulcerative colitis. , 1994, The New England journal of medicine.

[78]  M. Moritz,et al.  National transplantation Pregnancy Registry--outcomes of 154 pregnancies in cyclosporine-treated female kidney transplant recipients. , 1994, Transplantation.

[79]  D. F. Roberts,et al.  Age at menarche , 1994, The Lancet.

[80]  R. Scott,et al.  Acute pancreatitis secondary to 5-aminosalicylic acid in a child with ulcerative colitis. , 1993, Journal of pediatric gastroenterology and nutrition.

[81]  D. Faulds,et al.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. , 1993, Drugs.

[82]  W. Ray,et al.  Prenatal Use of Metronidazole and Birth Defects: No Association , 1993, Obstetrics and gynecology.

[83]  G. Benker,et al.  Glucocorticoid‐induced osteoporosis: pathogenesis, prevention and treatment, with special regard to the rheumatic diseases , 1993, Journal of internal medicine.

[84]  J. Teare,et al.  The mode of action of the aminosalicylates in inflammatory bowel disease , 1993 .

[85]  K. Motil,et al.  Disposition of Olsalazine and Metabolites in Breast Milk , 1993, Journal of clinical pharmacology.

[86]  M. Kamm,et al.  Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. , 1993, Gut.

[87]  P. Dale,et al.  Pancytopenia associated with low dose methotrexate therapy. A regional survey. , 1993, The Journal of rheumatology.

[88]  A. Macpherson,et al.  Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. , 1993, Gastroenterology.

[89]  R. Warnke,et al.  Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. , 1993, The New England journal of medicine.

[90]  M. Goldenberg,et al.  Methotrexate therapy of tubal pregnancy. , 1993, Human reproduction.

[91]  F. Arellano,et al.  Malignancies in rheumatoid arthritis patients treated with cyclosporin A. , 1993, British journal of rheumatology.

[92]  N. Jamieson,et al.  Cyclosporin absorption from microemulsion formulation in liver transplant recipient , 1993, The Lancet.

[93]  C. Holdsworth,et al.  Double blind trial of oral fluticasone propionate v prednisolone in the treatment of active ulcerative colitis. , 1993, Gut.

[94]  J. Lennard-jones,et al.  Oral fluticasone propionate compared with prednisolone in treatment of active Crohn's disease: a randomized double-blind multicentre study , 1993 .

[95]  G. Mullin,et al.  Lymphoma in inflammatory bowel disease , 2010, Cancer.

[96]  E. Scapa,et al.  Hepatotoxicity of 6-mercaptopurine in Crohn's disease. , 1992, The American journal of gastroenterology.

[97]  G. Klöppel,et al.  Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine. , 1992, Gastroenterology.

[98]  M. Mihatsch,et al.  Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. , 1992, The New England journal of medicine.

[99]  B. Kirschner,et al.  Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure. , 1992, Gastroenterology.

[100]  A. Astier,et al.  Pharmacokinetics and absolute rectal bioavailability of hydrocortisone acetate in distal colitis , 1992, Alimentary pharmacology & therapeutics.

[101]  T. Gaginella,et al.  Sulfasalazine. Multiplicity of action. , 1992, Digestive diseases and sciences.

[102]  K. Schroeder,et al.  Lung disease associated with orally administered mesalamine for ulcerative colitis. , 1992, Chest.

[103]  M. Hamadeh,et al.  Sulfasalazine-induced pulmonary disease. , 1992, Chest.

[104]  D. Cook,et al.  Safe use of glucocorticoids. How to monitor patients taking these potent agents. , 1992, Postgraduate medicine.

[105]  C. Holdsworth,et al.  Clinical tolerance to three 5‐aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine , 1992, Alimentary pharmacology & therapeutics.

[106]  R. Schlaghecke,et al.  The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. , 1992 .

[107]  N. Christy.  Pituitary-adrenal function during corticosteroid therapy. Learning to live with uncertainty. , 1992, The New England journal of medicine.

[108]  S. Schreiber,et al.  The mechanism of action of cyclosporin A and FK506. , 1992, Immunology today.

[109]  G. Crabtree,et al.  Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A , 1991, Nature.

[110]  S. Hanauer,et al.  Risk-Benefit Assessment of Drugs Used in the Treatment of Inflammatory Bowel Disease , 1991, Drug safety.

[111]  D. Silk,et al.  Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects. , 1991, Gut.

[112]  J. Rask-Madsen,et al.  Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. , 1990, Gut.

[113]  J. Lennard-jones,et al.  Safety of azathioprine in pregnancy in inflammatory bowel disease. , 1990, Gastroenterology.

[114]  H. Thomsen,et al.  Renographic monitoring of renal function in patients with Crohn's disease treated with low dose cyclosporin: a controlled study. , 1990, British medical journal.

[115]  S. Friis,et al.  Fatal myocarditis associated with mesalazine , 1990, The Lancet.

[116]  L. Sutherland.  Topical treatment of ulcerative colitis. , 1990, The Medical clinics of North America.

[117]  D. Jewell,et al.  Acetylation of 5-aminosalicylic acid by isolated human colonic epithelial cells. , 1990, Clinical science.

[118]  R. Modigliani,et al.  [Treatment of Crohn's disease with azathioprine or 6-mercaptopurine. Retrospective study of 126 cases]. , 1990, Gastroenterologie clinique et biologique.

[119]  A. Stuck,et al.  Risk of infectious complications in patients taking glucocorticosteroids. , 1989, Reviews of infectious diseases.

[120]  S. Meltzer,et al.  6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. , 1989, Annals of internal medicine.

[121]  R. Weinshilboum,et al.  Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism , 1989, Clinical pharmacology and therapeutics.

[122]  S. Hou.  Pregnancy in organ transplant recipients. , 1989, The Medical clinics of North America.

[123]  R. Kozarek,et al.  Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. , 1989, Annals of internal medicine.

[124]  N. Vakil,et al.  Steroid-related osteonecrosis in inflammatory bowel disease. , 1989, Gastroenterology.

[125]  J. Kremer,et al.  Methotrexate for Rheumatoid Arthritis , 1994 .

[126]  H. Maibach,et al.  Methotrexate in psoriasis: revised guidelines. , 1988, Journal of the American Academy of Dermatology.

[127]  J. G. Walker,et al.  Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double‐blind comparison with sulphasalazine , 1988, Alimentary pharmacology & therapeutics.

[128]  G. Searles,et al.  Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. , 1987, The Journal of rheumatology.

[129]  G. Koren,et al.  PHARMACOKINETIC CASE FOR GIVING 6-MERCAPTOPURINE MAINTENANCE DOSES AT NIGHT , 1987, The Lancet.

[130]  S. Riley,et al.  Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution. , 1987, Gut.

[131]  S. Flechner,et al.  Hepatobiliary complications of cyclosporine therapy following renal transplantation. , 1987, Transplantation proceedings.

[132]  S. Meltzer,et al.  Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. , 1986, Gastroenterology.

[133]  J. Kremer,et al.  The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. , 1986, Arthritis and rheumatism.

[134]  D. Nashel.  Is atherosclerosis a complication of long-term corticosteroid treatment? , 1986, The American journal of medicine.

[135]  J. Maddocks,et al.  Azathioprine suppresses the mixed lymphocyte reaction of patients with Lesch-Nyhan syndrome. , 1985, British journal of clinical pharmacology.

[136]  U. Klotz,et al.  Clinical Pharmacokinetics of Sulphasalazine, Its Metabolites and Other Prodrugs of 5-Aminosalicylic Acid , 1985, Clinical pharmacokinetics.

[137]  J. Markowitz,et al.  Peripheral neuropathy in Crohn's disease patients treated with metronidazole. , 1985, Gastroenterology.

[138]  L. Kinlen.  Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. , 1985, The American journal of medicine.

[139]  W. R. Porter,et al.  The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine. , 1985, Drug metabolism reviews.

[140]  M. Peppercorn.  Sulfasalazine: Pharmacology, Clinical Use, Toxicity, and Related New Drug Development , 1984 .

[141]  Korelitz Bi,et al.  The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. , 1984 .

[142]  P. Ebden,et al.  Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis. , 1984, British journal of clinical pharmacology.

[143]  G. Curt,et al.  The pharmacology and clinical use of methotrexate. , 1983, The New England journal of medicine.

[144]  K. Das,et al.  Sulfasalazine. Adverse effects and desensitization. , 1983, Digestive diseases and sciences.

[145]  R. Riccardi,et al.  Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? , 1983, The New England journal of medicine.

[146]  W. Jusko,et al.  Prednisolone disposition and protein binding in oral contraceptive users. , 1983, The Journal of clinical endocrinology and metabolism.

[147]  R. Goyer,et al.  Tixocortol pivalate, a corticosteroid with no systemic glucocorticoid effect after oral, intrarectal, and intranasal application , 1983, Clinical pharmacology and therapeutics.

[148]  G. Järnerot,et al.  Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy. , 1983, Scandinavian journal of gastroenterology.

[149]  S. Mandel.  Steroid myopathy. Insidious cause of muscle weakness. , 1982, Postgraduate medicine.

[150]  S. Hansen,et al.  5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. , 1982, Gastroenterology.

[151]  B. Huitfeldt,et al.  A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. , 1982, Gastroenterology.

[152]  O. Nielsen.  Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. , 1982, Scandinavian journal of gastroenterology.

[153]  C. Kumana,et al.  BECLOMETHASONE DIPROPIONATE ENEMAS FOR TREATING INFLAMMATORY BOWEL DISEASE WITHOUT PRODUCING CUSHING'S SYNDROME OR HYPOTHALAMIC PITUITARY ADRENAL SUPRESSION , 1982, The Lancet.

[154]  A. Hess,et al.  Effect of cyclosporin A on human lymphocyte responses in vitro. III. CsA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primed lymphocytes to TCGF. , 1982, Journal of immunology.

[155]  W. Ra,et al.  Azathioprine teratogenicity: review of the literature and case report. , 1981 .

[156]  B. Korelitz,et al.  Pregnancy in inflammatory bowel disease: Effect of sulfasalazine and corticosteroids on fetal outcome , 1981 .

[157]  G. Warden,et al.  Neutropenia and thrombocytopenia in renal allograft recipients treated with trimethoprim-sulfamethoxazole. , 1980, Annals of internal medicine.

[158]  J. Palek,et al.  Selective erythroid and magakaryocytic aplasia after sulfasalazine administration. , 1980, Archives of internal medicine.

[159]  B. Pasternack,et al.  Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. , 1980, The New England journal of medicine.

[160]  E. Housley,et al.  Raynaud's phenomenon induced by sulphasalazine. , 1980, Postgraduate medical journal.

[161]  H. Mekhjian,et al.  National Cooperative Crohn's Disease Study: adverse reactions to study drugs. , 1979, Gastroenterology.

[162]  R. Summers,et al.  National Cooperative Crohn's Disease Study: results of drug treatment. , 1979, Gastroenterology.

[163]  R. C. Hall,et al.  Presentation of the Steroid Psychoses , 1979, The Journal of nervous and mental disease.

[164]  G. J. Blackwell,et al.  Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation , 1979, Nature.

[165]  G. Järnerot,et al.  Sulphasalazine treatment during breast feeding. , 1979, Scandinavian journal of gastroenterology.

[166]  I. Griffiths,et al.  Sulphasalazine-induced lupus syndrome in ulcerative colitis. , 1977, British medical journal.

[167]  S. Truelove,et al.  AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINE , 1977, The Lancet.

[168]  L. Beeley,et al.  Megaloblastic anaemia associated with sulphasalazine treatment. , 1977, British medical journal.

[169]  H O Conn,et al.  Nonassociation of adrenocorticosteroid therapy and peptic ulcer. , 1976, The New England journal of medicine.

[170]  M. Eastwood,et al.  Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease , 1975, Clinical pharmacology and therapeutics.

[171]  M. Pospišil,et al.  Cytotoxic effects of 6-mercaptopurine on the limb-bud blastemal cells of rat embryos. , 1975, Teratology.

[172]  A. Chalmers.  Studies on the mechanism of formation of 5-mercapto-1-methyl-4-nitroimidazole, a metabolite of the immunosuppressive drug azathioprine. , 1974, Biochemical Pharmacology.

[173]  J. McManus,et al.  Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. , 1973, The New England journal of medicine.

[174]  D. Azarnoff,et al.  Clinical complications of corticosteroid therapy. A selected review. , 1973, The Medical clinics of North America.

[175]  I. Rosenberg,et al.  Impaired folic acid absorption in inflammatory bowel disease: effects of salicylazosulfapyridine (Azulfidine). , 1973, Gastroenterology.

[176]  H. Schröder,et al.  Absorption, metabolism, and excretion of salicylazosulfapyridine in man , 1972, Clinical pharmacology and therapeutics.

[177]  W. Swaim,et al.  Azulfidine agranulocytosis with bone marrow, megakaryocytosis, histiocytosis and plasmacytosis. , 1972, Minnesota medicine.

[178]  W. Jusko,et al.  Prednisone side-effects and serum-protein levels. A collaborative study. , 1971, Lancet.

[179]  R. Farmer,et al.  Treatment of ulcerative colitis with hydrocrotisone enemas: relationship of hydrocortisone absorption, adrenal suppression, and clinical response. , 1970, Diseases of the colon and rectum.

[180]  H. Genant,et al.  Pancreatitis as an adverse reaction to salicylazosulfapyridine. , 1970, The New England journal of medicine.

[181]  A. Sadeghi‐Nejad,et al.  The treatment of ulcerative colitis in children with alternate-day corticosteroids. , 1969, Pediatrics.

[182]  J. Ström.  Toxic epidermal necrolysis (Leyell's syndrome). A report on four cases with three deaths. , 1969, Scandinavian journal of infectious diseases.

[183]  J. Crowther.  Summer-term Blains , 1964, British medical journal.

[184]  W. Nelp.  Acute pancreatitis associated with steroid therapy. , 1961, Archives of internal medicine.

[185]  Smith Jv.  Bornholm disease in the tropics. , 1947 .

[186]  A. Sanders,et al.  Mycophenolic acid; an antibiotic from Penicillium brevicompactum Dlerckx. , 1946, Lancet.